What TECFIDERA Treats: Main Uses and Benefits

TECFIDERA is generally considered a Disease-Modifying Therapy (DMT) relevant for managing relapsing forms of multiple sclerosis (MS) in adults, including Clinically Isolated Syndrome (CIS), Relapsing-Remitting Disease (RRMS), and Active Secondary Progressive Disease (SPMS). Its therapeutic application is relevant for easing conditions characterized by periods of heightened symptoms.

---

The medication addresses conditions characterized by episodic neurological relapses and the long-term accumulation of physical impairment. The treatment is relevant for easing these acute events, which may contribute to a more consistent clinical course and helps ease the overall symptom burden. By assisting in slowing the rate at which irreversible disability progresses, TECFIDERA plays a role in managing symptoms that create noticeable physiological strain. This supportive action may assist with maintaining functional stability when symptoms are more noticeable, supporting general well-being during symptomatic phases.

---

Quick Fact Block

Quick Fact: Therapeutic Role in MS	Description
Main Use	Applied for managing relapsing forms of MS, including CIS, RRMS, and active SPMS.
Primary Benefit	Reduction in the frequency and severity of neurological relapses.
Long-Term Goal	Assisting in slowing down the progression of physical disability over time.
Disease Activity	Used for managing subclinical disease activity (new/enlarging lesions).

The eligibility for using TECFIDERA is strictly defined by regulatory authorities based on age, clinical status, and known hypersensitivity. The medicine is approved for adults and paediatric patients aged 13 years and older with relapsing forms of multiple sclerosis.

---

Contraindications and Restrictions

TECFIDERA is contraindicated in patients with a known hypersensitivity to dimethyl fumarate or any of its excipients. In European labeling, use is also contraindicated in patients with suspected or confirmed Progressive Multifocal Leukoencephalopathy (PML).

• Lymphocyte Status: Treatment should not be initiated in patients with severe lymphopenia (absolute lymphocyte count < 0.5 imes 10^9/L). Treatment must be discontinued if this severe lymphopenia persists for more than six months.
• Age: Safety and efficacy have not been established in children under 13 years of age.
• Organ Function: Caution should be used when treating patients with severe renal impairment, severe hepatic impairment, or severe active gastrointestinal disease, as studies have not been performed in these specific populations.
• Pregnancy/Lactation: Use during pregnancy is permitted only if the potential benefit justifies the potential risk to the fetus. It is not known if the drug passes into human milk.

TECFIDERA Interactions with other medicines and products

Official regulatory documents specify several interaction patterns for Dimethyl Fumarate. A primary consideration is the pharmacodynamic interaction with other immunosuppressive or immunomodulating therapies. Co-administration is a regulatory concern due to the potential for additive immune effects, which may increase the risk of serious infections, including Progressive Multifocal Leukoencephalopathy (PML). Similarly, combining TECFIDERA with other fumarate-containing medicinal products is generally avoided due to the potential for cumulative exposure to fumaric acid derivatives.

The medicine's metabolic and transport profile establishes that no clinically relevant pharmacokinetic interaction is expected with major drug-metabolizing CYP enzymes or P-glycoprotein (P-gp) transporters. In clinical studies, co-administration with Aspirin, Glatiramer acetate, or Interferon beta-1a resulted in no alteration of the drug's overall systemic exposure (AUC).

A documented drug-food interaction affects the rate of absorption: the co-administration of food causes a decreased maximum plasma concentration ( C max) of the active metabolite, Monomethyl Fumarate (MMF). However, the total exposure ( AUC) remains unchanged. Official regulatory labels do not document any mandatory drug-drug timing separation requirements or specific interaction cautions related to patient populations like those with hepatic impairment. The only formal contraindication is known hypersensitivity to the drug itself.

Cytoprotection: Cellular Defense Activation (Nrf2 Activation)

The active metabolite, Monomethyl Fumarate (MMF), engages the Nrf2 pathway, a mechanism regulating cellular cytoprotective responses. MMF modifies the repressor protein Keap1, causing Nrf2 to be released and translocate to the nucleus where it drives the transcription of antioxidant enzymes (e.g., HO-1). This action increases the cellular threshold for stress, specifically against damage caused by oxidative stress, a mechanism that is active in the Central Nervous System ( CNS) and periphery.

---

Immunomodulation: Modulation of Inflammatory Signaling ( NF-kappa B Inhibition)

Concurrently, MMF functions as an immunomodulator by inhibiting the master transcription factor NF-kappa B. By blocking NF-kappa B's nuclear activity, the drug suppresses the expression of various pro-inflammatory cytokines and chemokines (e.g., TNF-alpha and IL-1beta). This physiological consequence modulates the overall immune profile by influencing the ratio of pro-inflammatory versus anti-inflammatory cell types, thereby contributing to a decreased level of inflammatory activity.

How to Use TECFIDERA (Dimethyl Fumarate)

TECFIDERA is an orally administered medication provided as delayed-release capsules in strengths of 120 mg and 240 mg. Its use is guided by a specific titration schedule.

Official Dosing and Administration

Dosing Phase	Dosage and Frequency	Duration
Starting Dose	120 mg taken twice daily (BID)	The first 7 days
Maintenance Dose	240 mg taken twice daily (BID)	Starting on Day 8 onwards

All doses must be taken by swallowing the capsule whole. The capsule or its contents must not be crushed, chewed, divided, or sprinkled onto food, as this would compromise the delayed-release formulation. The medication may be taken with or without food; however, taking it with food may help reduce the incidence of flushing.

Special Use Instructions

• Missed Dose: If a dose is missed, it should be taken only if at least 4 hours remain before the next scheduled dose. Otherwise, the patient should skip the missed dose and resume the normal schedule. A double dose should not be taken to make up for a missed dose.
• Dose Reduction: For patients who cannot tolerate the 240 mg maintenance dose, a temporary reduction to 120 mg twice daily may be considered. The patient should attempt to resume the full maintenance dose within four weeks.

Research Evidence / Overview of Studies for TECFIDERA

Evidence for Use in Relapsing Forms of Multiple Sclerosis

The primary evidence for Dimethyl Fumarate (TECFIDERA) was gathered through large, international Phase 3 Randomized Controlled Trials (RCTs). These studies was evaluated in adult populations diagnosed with relapsing forms of MS, including those newly diagnosed and those previously treated with other therapies. The RCTs provided the basis for understanding how the medicine was associated with patterns of disease activity over a two-year period, primarily by observing outcomes in the active substance groups against a placebo group. The trials examined measured outcomes including relapse frequency and measures of disability progression.

Core Trial Outcomes: Relapse and Disability Measures

Research examined outcomes describing episodic or acute changes—specifically, the frequency of neurological relapses experienced by patients. The findings describe patterns observed in the studies where the active substance groups reported measured relapse rates that differed from those reported by the placebo groups. Similarly, studies monitored outcomes reflecting daily functioning or activity level, using a standard scale to measure changes in physical disability status. Research also explored time-to-event data related to confirmed disability progression, with data describing patterns related to the time measured for patients to reach confirmed progression markers during the trial period. This evidence contributes to understanding symptom patterns and how physical discomfort was monitored in the observed populations.

Trial Outcomes: MRI and Disease Activity

Studies also monitored the disease activity that was not always apparent through physical symptoms. The medicine was studied for its association with changes in new or active lesions on Magnetic Resonance Imaging (MRI) scans. Research highlights changes measured during the study period in a controlled setting, where the number of new or active lesions detected on MRI scans in the active substance groups were reported to be different compared to the placebo groups.

---

Comparative Research and Placebo-Controlled Evidence

The main regulatory research primarily involved comparing the medicine against a placebo over the initial two years of the pivotal trials. These study designs allow researchers to establish the patterns of disease activity observed when the medicine is used versus when an inactive substance is used. Additionally, in one of the pivotal trials, the medicine was evaluated in a setting that included an established active comparator (glatiramer acetate), allowing research to observe and document the measured outcomes between these two active substances in the study populations. This evidence contributes to the broader evidence landscape but does not include direct comparisons against many other currently available therapeutic options.

---

Long-Term Studies and Follow-up

The efficacy period of the primary regulatory studies was limited to two years. To address the need for information on a long-term chronic condition, the research explored outcomes over extended periods through open-label extension studies, such as the ENDORSE trial, which followed patients for up to 13 years. This long-term research observed responses over defined time intervals, tracking relapse rates and disability progression in the subset of patients who continued into the extension phase. However, because these extension studies lack a concurrent placebo or blinded control group, the certainty regarding sustained long-term outcomes is reduced when compared to the initial controlled trials.

Common questions about TECFIDERA (FAQ)

Q: Is TECFIDERA considered a chemotherapy drug?

A: Official drug classifications describe TECFIDERA as a disease-modifying therapy (DMT) and an immunomodulator. It is not classified as a chemotherapy drug in regulatory documents. The medicine's action is defined by activating a pathway related to cellular protection and by modulating (adjusting) the immune system.

---

Q: Does TECFIDERA weaken the immune system?

A: TECFIDERA is classified as an immunomodulator because it affects how the immune system functions. A commonly reported adverse reaction documented in official information is lymphopenia, which is a decrease in the number of certain white blood cells (lymphocytes) in the blood.

---

Q: Why do some people stop taking TECFIDERA?

A: Regulatory information outlines specific conditions that may lead to the discontinuation of treatment. These include the development of a rare brain infection called Progressive Multifocal Leukoencephalopathy (PML) or experiencing prolonged severe lymphopenia (low white blood cell counts) that persists for more than six months.

---

Q: Are there any long-term effects of taking TECFIDERA?

A: Studies that followed patients over extended periods, sometimes for more than a decade, have been conducted. Official data from these long-term extension studies have not identified new safety concerns that differ from the established safety profile seen during the initial controlled trials.

---

Q: Does the efficacy of TECFIDERA decrease over time?

A: Clinical data from long-term extension studies describe patterns of sustained outcomes on relapse rates and disability progression over several years of continuous treatment. This research evidence indicates that the therapeutic response has been observed to persist over defined time intervals.

---

Q: Does taking TECFIDERA require an injection?

A: No, TECFIDERA is an orally administered medicine. It is taken by mouth as a delayed-release capsule. The route of administration is defined in the official product information.

---

Q: Are there different dosages of TECFIDERA available?

A: Yes, the medicine is supplied as delayed-release capsules in different strengths. These strengths are defined in the official product labeling and are used for different phases of treatment.

---

Q: What is the time it takes for side effects to usually wear off after starting TECFIDERA?

A: Official product information notes that common side effects, such as flushing and gastrointestinal issues like diarrhea or nausea, typically begin early in treatment, often within the first month. These effects are reported to often lessen over time as the body adjusts to the medication.

---

Q: How long can a person stay on TECFIDERA treatment?

A: TECFIDERA is intended as a therapy for a chronic condition. Clinical extension studies have followed patients who remained on continuous treatment for up to 13 years, confirming its potential use as an extended, long-term therapy.

---

Q: How is TECFIDERA typically stored (e.g., for travel)?

A: The official storage requirements mandate keeping the medicine at controlled room temperature, generally between 15 C and 30 C (59 F and 86 F). To maintain its stability, it must be kept in its original container, closed, and protected from light and moisture.

---

Q: Does TECFIDERA affect my ability to drive or operate machinery?

A: Official product information states that no specific studies have been conducted to determine the effects of TECFIDERA on a person's ability to safely drive or operate machinery.

---

Q: Is TECFIDERA safe to use during pregnancy or while breastfeeding?

A: Official guidance states that use during pregnancy is permitted only if the potential benefit is determined to justify the potential risk to the fetus. For nursing mothers, it is not known if the drug passes into human breast milk, and caution is therefore advised.

---

Q: Can people with other chronic conditions use TECFIDERA?

A: Regulatory documents advise caution when treating patients who have pre-existing severe renal impairment (kidney issues), severe hepatic impairment (liver issues), or severe active gastrointestinal disease. This caution is noted because the drug has not been extensively studied in these specific populations.

---

Q: Can TECFIDERA cause issues with my kidneys?

A: The official product information advises caution in patients with pre-existing severe renal impairment (a serious kidney condition). This is due to a lack of specific studies performed in this patient group.

---

Q: Can alcohol be consumed while taking TECFIDERA?

A: Official guidance requires patients to inform their healthcare provider about their alcohol consumption. This disclosure allows the provider to assess the individual's use conditions and any potential interactions.

---

Q: Can TECFIDERA be taken with vitamins or supplements?

A: Official guidance requires informing a healthcare provider about all medicines, including over-the-counter products, vitamins, and herbal supplements they are taking. This ensures that the provider can check for any potential interaction patterns.

---

Q: Does TECFIDERA interact with cold or flu medicines?

A: Official guidance requires informing a healthcare provider of all over-the-counter medicines, which would include cold or flu treatments. This allows the provider to assess the risk of potential interactions before use.

---

Q: Is TECFIDERA a new drug or has it been around for a while?

A: The specific TECFIDERA drug product was first approved by the U.S. Food and Drug Administration (FDA) on March 27, 2013, establishing its market history.

---

Q: Is TECFIDERA available as a generic medicine?

A: Yes, generic versions of dimethyl fumarate, which is the active ingredient in TECFIDERA, have been approved by the FDA and are available.

How to Store and Dispose of TECFIDERA

TECFIDERA must be stored according to specific environmental and temperature controls to maintain its stability. The official requirements mandate storage at controlled room temperature, maintaining a range between 15 C and 30 C (59 F and 86 F). The product must be kept from freezing and away from heat.

To ensure product integrity, the medicine must be stored in its original container, kept closed, and protected from light and moisture. For safety, it must be stored out of the reach of children.

Disposal protocols require that outdated or unused medicine not be kept. Patients should consult a healthcare professional or pharmacist for guidance on discarding the product, often recommending an immediate drug take-back option.